CD8A and neoplasm: Though the same benefit of dual LAG‐3/PD‐1 blockade over PD‐1 blockade alone was not observed in double positive tumor Ag‐specific CD8+ TIL isolated from ovarian cancer patients, it was achieved when both co‐inhibitors were targeted during the initial priming of Ag‐specific T cells isolated from PBL.166